National Policy Resources—Local Advocacy Results

As cancer care professionals who experience the challenges of providing quality cancer care first-hand, MSCO members are well positioned to educate decision-makers on how coverage and reimbursement issues affect community oncology. State and federal legislation can have a significant impact on the financial viability of local cancer programs, which is why it's so important that our members make their voices heard.

In an effort to provide resources needed to effectively advocate on the issues that are important to them, our redesigned advocacy webpage features activity from the Centers for Medicare & Medicaid Services (CMS), national healthcare coverage through the Association of Community Cancer Centers (ACCC), local news articles and webinars, and more.

We want to hear from you! If there is a specific piece of legislation you want to know more about, an important resource we're missing, or if you want to get more involved, please contact us!


State Advocacy

MSCO and ASCO Together Support Efforts to Control PBMs Influence Over Patient’s Pharmacy Services

MSCO and ASCO jointly support a pair of bills (HF 544 and SF 482) that target anti-competitive pharmacy benefit managers (PBMs) business practices.  The bills would prohibit PBMs and payers from requiring oncologists to administer chemotherapy agents that have been prepared outside the physician’s office by an entity under contract with the payer. Both bills have passed their first committee hearings and are now in their second committees.

Read Letter (HF 544) Read Letter (SF 482)

MSCO and ASCO Submit Letter of Concern Over Upper Payment Language in SF 168

The Minnesota Society Clinical Oncology Society (MSCO) and the Association for Clinical Oncology (ASCO) have issued a letter to Minnesota legislature showing concerns that Section 9 of SF 168 – Prescription Drug Affordability Board, if passed, would jeopardize access to necessary care for Minnesota patients with cancer.

Read Letter

MSCO Joins in Support Letter for HF 3717 and Its Provisions to Address Out-of-Pocket Costs for Patients

The Minnesota Society of Clinical Oncology (MSCO) joined national organizations in a support letter for copy-only bill language in HF 3717 inspired by HF 633 (Bierman) and SF 365 (Nelson). This language would give consumers who purchase coverage on the individual and small-group markets the option of buying a plan that restructures the out-of-pocket costs for prescription drugs.

Read Letter

Federal Advocacy

MSCO Joins Coalition Letter Urging Addition of the Cures 2.0 Concept Paper Title IV Provisions in the Next COVID-19 Relief Package

The Minnesota Society of Clinical Oncology (MSCO) joined in a coalition letter to congressional leadership urging that Congress include the 21st Century Cures 2.0 concept paper, recently released by Representatives Diana DeGette and Fred Upton in upcoming legislation to further address the COVID-19 public health crisis. Specifically the letter urges leadership to include policy to provide Medicaid coverage of the routine care costs of clinical trials participation for patients with life-threatening conditions in every state. This critical protection is championed by Representatives Ben Ray Luján and Gus Bilirakis in the Clinical Treatment Act (H.R. 913).

 

FROM THE ACCCBUZZ BLOG

  • An Update on Healthcare Legislation at the State Level
    By Christian G. Downs, MHA, JD
    March 22, 2023
    If you are looking for legislative action, look no further than your state's legislatures. Most—if not all—states have had issues relating to oncology care and healthcare in general come up during their 2023 sessions.
  • ACCC Announces its 2023 Advocacy Agenda
    March 07, 2023
    For 2023, ACCC members have identified four core areas of focus (e.g., reimbursement, utilization management, provider-patient choice), among a larger set of issues and concerns, that the association will be supporting this year.
  • ACCC Recognizes National Caregivers Day: Analyzing a Mental Health Crisis
    February 17, 2023
    Today is National Caregivers Day, and ACCCBuzz analyzes the current mental health crisis that is affecting the caregivers of loved ones everywhere.

Advocacy In the News

CMS Releases CY 2020 Final Medicare Payment Rules

On Friday, Nov. 1, the Centers for Medicare & Medicaid Services (CMS) released the final calendar year (CY) 2020 Hospital Outpatient Prospective Payment System (OPPS) rule (CMS-1717-FC) and the final CY 2020 Physician Fee Schedule (PFS) and Quality Payment Rule (CMS 1715-F).

The CMS CY 2020 OPPS fact sheet states that:
As finalized in last year’s rule, CMS is completing the two-year phase-in of the method to reduce unnecessary utilization in outpatient services by addressing payments for clinic visits furnished in the off-campus hospital outpatient setting.

And further states:
We acknowledge that the United States District Court for the District of Columbia vacated the volume control policy for CY 2019 and we are working to ensure affected 2019 claims for clinic visits are paid consistent with the court’s order.  We do not believe it is appropriate at this time to make a change to the second year of the two-year phase-in of the clinic visit policy. The government has appeal rights, and is still evaluating the rulings and considering, at the time of this writing, whether to appeal from the final judgment.

340B Drug Pricing Program
The CMS 2020 OPPS final rule fact sheet states that:
For CY 2020, CMS is finalizing its proposal to continue to pay an adjusted amount of ASP minus 22.5 percent for separately payable drugs or biologicals that are acquired through the 340B Program. In the proposed rule, CMS acknowledged that the CY 2018 and 2019 OPPS payment policies for 340B-acquired drugs are the subject of ongoing litigation, and the agency is currently appealing the decision in the United States Court of Appeals for the District of Columbia Circuit. 

Access full CMS Fact Sheet on the CY 2020 OPPS final rule.
Access the CY 2020 OPPS final rule here.

CY 2020 Physician Fee Schedule (PFS) and Quality Payment Rule
The CMS fact sheet on the final CY 2020 PFS and Quality Payment rule states that:
. . . we are aligning our E/M coding with changes adopted by the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel for office/outpatient E/M visits. The CPT coding changes retain 5 levels of coding for established patients, reduce the number of levels to 4 for office/outpatient E/M visits for new patients, and revise the code definitions. The CPT code changes also revise the times and medical decision making process for all of the codes, and requires performance of history and exam only as medically appropriate. The CPT code changes also allow clinicians to choose the E/M visit level based on either medical decision making or time.

Physician Supervision Requirements for Physician Assistants
In its 2020 PFS file rule fact sheet, the agency states:
We are updating our regulation on physician supervision of PAs to give PAs greater flexibility to practice more broadly in the current health care system in accordance with state law and state scope of practice. In the absence of any state rules, CMS is finalizing a revision to the current supervision requirement to clarify that physician supervision is a process in which a PA has a working relationship with one or more physicians to supervise the delivery of their health care services. Such physician supervision is evidenced by documenting the PA’s scope of practice and indicating the working relationship(s) the PA has with the supervising physician(s) when furnishing professional services.

Access the CMS 2020 PFS final rule fact sheet.
Access the 2020 QPP Final Rule Fact Sheet 
Access the CMS 2020 PFS final rule here.

ACCC's policy team is analyzing these final rules and will provide more in-depth information to members soon.

Posted 11/01/2019



Oncology State Societies at ACCC: Snapshot from the 2022 ASCO Annual Meeting

In this clip, Stephanie Van Winkle, Executive Director of the Oncology State Societies at ACCC, gives an overview of the important work the Oncology State Societies does to empower its members around state and federal advocacy issues, and help them support cancer care delivery in their state. Join today


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
msco-minnesota.com
Email Us